» Articles » PMID: 22450871

Rhes: a GTP-binding Protein Integral to Striatal Physiology and Pathology

Overview
Publisher Springer
Date 2012 Mar 28
PMID 22450871
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Rhes, the Ras Homolog Enriched in Striatum, is a GTP-binding protein whose gene was discovered during a screen for mRNAs preferentially expressed in rodent striatum. This 266 amino acid protein is intermediate in size between small Ras-like GTP-binding proteins and α-subunits of heterotrimeric G proteins. It is most closely related to another Ras-like GTP-binding protein termed Dexras1 or AGS1. Although subsequent studies have shown that the rhes gene is expressed in other brain areas in addition to striatum, the striatal expression level is relatively high, and Rhes protein is likely to play a vital role in striatal physiology and pathology. Indeed, it has recently been shown to interact with the Huntingtin protein and play a pivotal role in the selective vulnerability of striatum in Huntington's disease (HD). Not surprisingly, Rhes can interact with multiple proteins to affect striatal physiology at multiple levels. Functional studies have indicated that Rhes plays a role in signaling by striatal G protein-coupled receptors (GPCR), although the details of the mechanism remain to be determined. Rhes has been shown to bind to both α- and β-subunits of heterotrimeric G proteins and to affect signaling by both Gi/o- and Gs/olf-coupled receptors. In this context, Rhes can be classified as a member of the family of accessory proteins to GPCR signaling. With documented effects in dopamine- and opioid-mediated behaviors, an interaction with thyroid hormone systems and a role in HD pathology, Rhes is emerging as an important protein in striatal physiology and pathology.

Citing Articles

Rhes, a striatal enriched protein, regulates post-translational small-ubiquitin-like-modifier (SUMO) modification of nuclear proteins and alters gene expression.

Rivera O, Sharma M, Dagar S, Shahani N, Ramlrez-Jarquln U, Crynen G Cell Mol Life Sci. 2024; 81(1):169.

PMID: 38589732 PMC: 11001699. DOI: 10.1007/s00018-024-05181-8.


Loss of Hap1 selectively promotes striatal degeneration in Huntington disease mice.

Liu Q, Cheng S, Yang H, Zhu L, Pan Y, Jing L Proc Natl Acad Sci U S A. 2020; 117(33):20265-20273.

PMID: 32747555 PMC: 7443904. DOI: 10.1073/pnas.2002283117.


Rhes Tunnels: A Radical New Way of Communication in the Brain's Striatum?.

Subramaniam S Bioessays. 2020; 42(6):e1900231.

PMID: 32236969 PMC: 7310467. DOI: 10.1002/bies.201900231.


Exaggerated mitophagy: a weapon of striatal destruction in the brain?.

Subramaniam S Biochem Soc Trans. 2020; 48(2):709-717.

PMID: 32129826 PMC: 7200642. DOI: 10.1042/BST20191283.


The striatal-enriched protein Rhes is a critical modulator of cocaine-induced molecular and behavioral responses.

Napolitano F, De Rosa A, Russo R, Di Maio A, Garofalo M, Federici M Sci Rep. 2019; 9(1):15294.

PMID: 31653935 PMC: 6814836. DOI: 10.1038/s41598-019-51839-w.


References
1.
Subramaniam S, Napolitano F, Mealer R, Kim S, Errico F, Barrow R . Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci. 2011; 15(2):191-3. PMC: 3267880. DOI: 10.1038/nn.2994. View

2.
Bonacci T, Mathews J, Yuan C, Lehmann D, Malik S, Wu D . Differential targeting of Gbetagamma-subunit signaling with small molecules. Science. 2006; 312(5772):443-6. DOI: 10.1126/science.1120378. View

3.
Lee F, Baiamonte B, Spano D, Lahoste G, Soignier R, Harrison L . Mice lacking rhes show altered morphine analgesia, tolerance, and dependence. Neurosci Lett. 2010; 489(3):182-6. PMC: 3035432. DOI: 10.1016/j.neulet.2010.12.012. View

4.
LaHoste G, Marshall J . Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse. 1992; 12(1):14-26. DOI: 10.1002/syn.890120103. View

5.
Chan S, Monks L, Gao H, Deaville P, Morgan N . Identification of the monomeric G-protein, Rhes, as an efaroxan-regulated protein in the pancreatic beta-cell. Br J Pharmacol. 2002; 136(1):31-6. PMC: 1762110. DOI: 10.1038/sj.bjp.0704680. View